Sarepta Therapeutics, Inc. (SRPT) shareholders
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
108M of 106M shares
Institutional holders
323
49 new, 65 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $417.41K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 16,642,620 | 15.80% | 13G (passive) amendment | Jun 30, 2026 |
| Vanguard Portfolio Management | 8,499,421 | 8.05% | 13G (passive) amendment | Jun 30, 2026 |
| AQR Capital Management, LLC Joint filing with AQR Capital Management Holdings, LLC (7.73%) | 8,104,869 | 7.73% | 13G (passive) | Dec 31, 2025 |
| State Street Corporation | 7,412,275 | 7.00% | 13G (passive) | Sep 30, 2026 |
| Vanguard Capital Management | 5,369,116 | 5.11% | 13G (passive) | Mar 31, 2026 |
| AQR Capital Management Holdings, LLC Joint filing with AQR Capital Management, LLC (5.05%) | 5,329,691 | 5.05% | 13G (passive) amendment | Jun 30, 2026 |
| David E. Shaw Joint filing with D. E. Shaw & Co., L.P. (5.10%) | 5,059,912 | 5.10% | 13G (passive) | Jul 18, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SRPT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,994,958 | 17.98% | $341.34M | +4,239,681 | 0.01% |
| State Street Corp | 8,916,090 | 8.44% | $160.22M | +2,302,776 | 0.00% |
| Vanguard Portfolio Management LLC | 8,377,470 | 7.93% | $150.54M | +1,736,778 | 0.01% |
| Two Sigma Investments, LP | 4,598,735 | 4.35% | $82.64M | +5,540 | 0.06% |
| Vanguard Capital Management LLC | 4,591,755 | 4.35% | $82.51M | +13,520 | 0.00% |
| First Trust Advisors LP | 4,365,951 | 4.13% | $78.46M | +230,163 | 0.05% |
| Aqr Capital Management LLC | 4,325,689 | 4.10% | $76.87M | −2,107,423 | 0.03% |
| Geode Capital Management, LLC | 2,771,758 | 2.62% | $49.82M | +782,962 | 0.00% |
| Erste Asset Management GmbH | 2,568,945 | 2.43% | $45.51M | −400,000 | 0.35% |
| Marshall Wace, Llp | 2,206,022 | 2.09% | $39.64M | +1,480,954 | 0.03% |
| Morgan Stanley | 2,202,641 | 2.09% | $39.58M | −394,352 | 0.00% |
| abrdn plc | 2,194,948 | 2.08% | $39.44M | −123,942 | 0.06% |
| Bank Of America Corp /De/ | 2,055,985 | 1.95% | $36.95M | −89,941 | 0.00% |
| Goldman Sachs Group Inc | 2,042,501 | 1.93% | $36.70M | +964,249 | 0.00% |
| UBS Group AG | 1,624,415 | 1.54% | $29.19M | −608,044 | 0.00% |
| Federated Hermes, Inc. | 1,590,331 | 1.51% | $28.58M | −195,690 | 0.04% |
| Northern Trust Corp | 1,210,732 | 1.15% | $21.76M | +486,473 | 0.00% |
| Millennium Management LLC | 1,193,468 | 1.13% | $21.45M | −28,214 | 0.01% |
| T. Rowe Price Investment Management, Inc. | 1,156,083 | 1.09% | $20.78M | +22,775 | 0.01% |
| Citigroup Inc | 1,155,006 | 1.09% | $20.76M | +7,358 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 323 | 108M | 100.0% | 49 / 98 | 118 / 65 | 22M | 17M |
| Q1 2026 | 344 | 103M | 97.4% | 50 / 109 | 130 / 48 | 31M | 10M |
| Q4 2025 | 348 | 94M | 88.9% | 74 / 137 | 90 / 42 | 20M | 14M |
| Q3 2025 | 320 | 87M | 82.8% | 65 / 109 | 105 / 106 | 26M | 22M |
| Q2 2025 | 363 | 83M | 78.9% | 64 / 160 | 89 / 128 | 31M | 34M |
| Q1 2025 | 430 | 87M | 82.2% | 71 / 147 | 148 / 101 | 11M | 11M |
| Q4 2024 | 465 | 88M | 83.3% | 78 / 158 | 157 / 64 | 10M | 10M |
| Q3 2024 | 458 | 89M | 84.4% | 58 / 171 | 158 / 82 | 21M | 12M |
| Q2 2024 | 485 | 91M | 86.0% | 120 / 178 | 131 / 45 | 15M | 11M |
| Q1 2024 | 415 | 87M | 82.3% | 77 / 144 | 123 / 55 | 10M | 8M |
| Q4 2023 | 396 | 85M | 80.2% | 75 / 123 | 140 / 66 | 15M | 14M |
| Q3 2023 | 395 | 84M | 79.1% | 50 / 155 | 125 / 55 | 12M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
307 funds held SRPT in Q2 2026, 75% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SRPT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 6,362,052 | 6.02% | $114.33M | 0.10% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,460,837 | 4.22% | $80.16M | 0.75% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 3,583,400 | 3.39% | $64.39M | 2.29% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,187,072 | 3.02% | $57.27M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,697,422 | 2.55% | $48.47M | 0.06% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,297,038 | 2.17% | $41.28M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,332,977 | 1.26% | $23.95M | 0.05% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,204,690 | 1.14% | $21.65M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,137,988 | 1.08% | $16.91M | 0.05% | Jul 31, 2026 |
| Federated Hermes MDT Mid Cap Growth Fund | 1,106,479 | 1.05% | $16.44M | 0.25% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 968,181 | 0.92% | $17.40M | 0.10% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 908,742 | 0.86% | $16.33M | 0.11% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 877,546 | 0.83% | $15.77M | 0.13% | Jun 30, 2026 |
| iShares Biotechnology ETF | 718,900 | 0.68% | $12.92M | 0.14% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 699,514 | 0.66% | $12.57M | 0.11% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Severino | Chief Executive Officer, Director | 756,104 | 0.72% | Jul 29, 2026 |
| Douglas S. Ingram | Chief Executive Officer, Director | 659,849 | 0.62% | Dec 9, 2025 |
| Ian Michael Estepan | Chief Operating Officer | 177,184 | 0.17% | Sep 8, 2026 |
| Louise Rodino-Klapac | President, R&D and Tech Ops | 203,900 | 0.19% | Sep 8, 2026 |
| Cristin Rothfuss | EVP, General Counsel | 115,519 | 0.11% | Sep 8, 2026 |
| Ryan Ho-Yan Wong | Chief Financial Officer | 121,792 | 0.12% | Sep 8, 2026 |
| Bilal Arif | Chief Tech Ops Officer | 24,224 | 0.02% | Aug 6, 2025 |
| Dallan Murray | Chief Customer Officer | 29,926 | 0.03% | Mar 11, 2025 |
| M. Kathleen Behrens | Director | 224,357 | 0.21% | Jun 5, 2026 |
| Claude Nicaise | Director | 48,407 | 0.05% | Jun 5, 2026 |
| Deirdre P. Connelly | Director | 22,100 | 0.02% | Jun 5, 2026 |
| Richard Barry | Director | 3,233,542 | 3.06% | Jun 5, 2026 |
| Hans Lennart Rudolf Wigzell | Director | 42,098 | 0.04% | Jun 5, 2026 |
| Kathryn Jean Boor | Director | 25,138 | 0.02% | Jun 5, 2026 |
| Stephen Mayo | Director | 18,640 | 0.02% | Jun 5, 2026 |
| Michael Andrew Chambers | Director | 504,027 | 0.48% | Jun 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Louise Rodino-Klapac President, R&D and Tech Ops | Sep 4, 2026 | Tax withholding | −21,423 | $22.22 | $476.02K | 203,900 |
| Ian Michael Estepan Chief Operating Officer | Sep 4, 2026 | Tax withholding | −24,799 | $22.22 | $551.03K | 177,184 |
| Ryan Ho-Yan Wong Chief Financial Officer | Sep 4, 2026 | Tax withholding | −13,272 | $22.22 | $294.90K | 121,792 |
| Cristin Rothfuss EVP, General Counsel | Sep 4, 2026 | Tax withholding | −22,025 | $22.22 | $489.40K | 115,519 |
| Michael Severino Chief Executive Officer, Director | Jul 28, 2026 | Award | +756,104 | – | – | 756,104 |
| Richard Barry Director | Jun 4, 2026 | Award | +16,875 | – | – | 2,983,542 |
| Stephen Mayo Director | Jun 4, 2026 | Award | +16,875 | – | – | 18,640 |
| Michael Andrew Chambers Director | Jun 4, 2026 | Award | +16,875 | – | – | 27,535 |
| Hans Lennart Rudolf Wigzell Director | Jun 4, 2026 | Award | +16,875 | – | – | 42,098 |
| Deirdre P. Connelly Director | Jun 4, 2026 | Award | +16,875 | – | – | 22,100 |
| Kathryn Jean Boor Director | Jun 4, 2026 | Award | +16,875 | – | – | 25,138 |
| Claude Nicaise Director | Jun 4, 2026 | Award | +16,875 | – | – | 48,407 |
| M. Kathleen Behrens Director | Jun 4, 2026 | Award | +16,875 | – | – | 214,357 |
| Stephen Mayo Director | Mar 12, 2026 | Sale | −7,239 | $17.02 | $123.21K | 1,765 |
| Cristin Rothfuss EVP, General Counsel | Mar 11, 2026 | Tax withholding | −974 | $17.03 | $16.59K | 137,544 |
| Ryan Ho-Yan Wong Chief Financial Officer | Mar 11, 2026 | Tax withholding | −256 | $17.03 | $4.36K | 135,064 |
| Ian Michael Estepan Chief Operating Officer | Mar 11, 2026 | Tax withholding | −1,097 | $17.03 | $18.68K | 201,983 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 11, 2026 | Tax withholding | −948 | $17.03 | $16.14K | 225,323 |
| Ryan Ho-Yan Wong Chief Financial Officer | Mar 9, 2026 | Tax withholding | −162 | $16.95 | $2.75K | 135,433 |
| Ryan Ho-Yan Wong Chief Financial Officer | Mar 9, 2026 | Tax withholding | −113 | $16.95 | $1.92K | 135,320 |
| Cristin Rothfuss EVP, General Counsel | Mar 9, 2026 | Tax withholding | −484 | $16.95 | $8.20K | 138,864 |
| Cristin Rothfuss EVP, General Counsel | Mar 9, 2026 | Tax withholding | −346 | $16.95 | $5.86K | 138,518 |
| Ian Michael Estepan Chief Operating Officer | Mar 9, 2026 | Tax withholding | −583 | $16.95 | $9.88K | 203,080 |
| Ian Michael Estepan Chief Operating Officer | Mar 9, 2026 | Tax withholding | −1,036 | $16.95 | $17.56K | 203,663 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 9, 2026 | Tax withholding | −504 | $16.95 | $8.54K | 227,166 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 9, 2026 | Tax withholding | −895 | $16.95 | $15.17K | 226,271 |
| Cristin Rothfuss EVP, General Counsel | Mar 2, 2026 | Tax withholding | −408 | $16.20 | $6.61K | 139,348 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 2, 2026 | Tax withholding | −3,718 | $16.20 | $60.23K | 228,437 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 2, 2026 | Tax withholding | −767 | $16.20 | $12.43K | 227,670 |
| Ryan Ho-Yan Wong Chief Financial Officer | Mar 2, 2026 | Tax withholding | −450 | $16.20 | $7.29K | 135,595 |
| Ian Michael Estepan Chief Operating Officer | Mar 2, 2026 | Tax withholding | −3,301 | $16.20 | $53.48K | 205,574 |
| Ian Michael Estepan Chief Operating Officer | Mar 2, 2026 | Tax withholding | −875 | $16.20 | $14.18K | 204,699 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 1, 2026 | Option exercise | +8,125 | – | – | 232,155 |
| Ian Michael Estepan Chief Operating Officer | Mar 1, 2026 | Option exercise | +8,125 | – | – | 208,875 |
| Ian Michael Estepan Chief Operating Officer | Feb 26, 2026 | Option exercise | +5,381 | $13.71 | $73.77K | 200,750 |
| Ian Michael Estepan Chief Operating Officer | Feb 26, 2026 | Option exercise | +2,069 | $13.71 | $28.37K | 195,369 |
| Claude Nicaise Director | Jan 29, 2026 | Option exercise | +10,500 | $13.71 | $143.96K | 38,312 |
| Claude Nicaise Director | Jan 29, 2026 | Tax withholding | −6,780 | $21.23 | $143.94K | 31,532 |
| M. Kathleen Behrens Director | Jan 27, 2026 | Tax withholding | −6,494 | $22.17 | $143.97K | 197,482 |
| M. Kathleen Behrens Director | Jan 27, 2026 | Option exercise | +10,500 | $13.71 | $143.96K | 203,976 |
| Ian Michael Estepan Chief Operating Officer | Dec 16, 2025 | Sale | −13,187 | $22.31 | $294.20K | 193,300 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +96,541 | – | – | 659,849 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +269,542 | – | – | 929,391 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +50,000 | – | – | 440,307 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +50,000 | – | – | 490,307 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +73,001 | – | – | 563,308 |
| Ryan Ho-Yan Wong Chief Financial Officer | Dec 1, 2025 | Tax withholding | −78 | $20.96 | $1.63K | 136,045 |
| Ryan Ho-Yan Wong Chief Financial Officer | Dec 1, 2025 | Tax withholding | −80 | $20.96 | $1.68K | 136,123 |
| Cristin Rothfuss EVP, General Counsel | Nov 28, 2025 | Tax withholding | −229 | $21.12 | $4.84K | 139,756 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Nov 17, 2025 | Tax withholding | −4,582 | $18.42 | $84.40K | 224,030 |
| Cristin Rothfuss EVP, General Counsel | Sep 3, 2025 | Award | +93,875 | – | – | 114,985 |
| Cristin Rothfuss EVP, General Counsel | Sep 3, 2025 | Award | +25,000 | – | – | 139,985 |
| Ryan Ho-Yan Wong Chief Financial Officer | Sep 3, 2025 | Award | +93,875 | – | – | 111,203 |
| Ryan Ho-Yan Wong Chief Financial Officer | Sep 3, 2025 | Award | +25,000 | – | – | 136,203 |
| Ian Michael Estepan Chief Operating Officer | Sep 3, 2025 | Award | +93,875 | – | – | 156,487 |
| Ian Michael Estepan Chief Operating Officer | Sep 3, 2025 | Award | +50,000 | – | – | 206,487 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Sep 3, 2025 | Award | +50,000 | – | – | 228,612 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Sep 3, 2025 | Award | +93,875 | – | – | 178,612 |
| Ryan Ho-Yan Wong Chief Financial Officer | Jul 31, 2025 | Tax withholding | −327 | $16.42 | $5.37K | 17,328 |
| Richard Barry Director | May 16, 2025 | Option exercise | +12,350 | $32.63 | $402.98K | 2,966,667 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
19.41%
19M shares short
Days to cover
7.8
At 2M shares a day
Change since last report
-13.6%
From 22M shares
Short volume, 20 days
46.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sarepta Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 33,269 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen Mayo Director | Mar 12, 2026 | 7,239 | $123.18K | Mar 12, 2026 | Restricted Stock |
| Ian Michael Estepan Officer | Dec 16, 2025 | 13,187 | $294.15K | Dec 16, 2025 | Exercised Shares |
| Sarepta Therapeutics, Inc. Shareholder | Aug 13, 2025 | 9,265,312 | $185.21M | Aug 13, 2025 | The common stock reported herein was acquired by Sarepta Therapeutics Investments, Inc., a wholly owned subsidiary of Sarepta Therapeutics, Inc., in a private placement transaction. |
| Claude Nicaise Director | Mar 12, 2025 | 2,491 | $248.23K | Mar 12, 2025 | STOCK OPTION EXERCISE |
| Hans Lennart Rudolf Wigzell Director | Dec 12, 2024 | 10,500 | $1.31M | Dec 12, 2024 | STOCK OPTION EXERCISE |
| Kathryn Jean Boor Director | Dec 5, 2024 | 1,636 | $205.40K | Dec 5, 2024 | RESTRICTED STOCK |
| Ian Michael Estepan Officer | Aug 30, 2024 | 5,985 | $822.13K | Aug 30, 2024 | RESTRICTED STOCK |
| Bilal Arif Officer | Jun 25, 2024 | 3,898 | $638.69K | Jun 25, 2024 | Performance Stock Units |
| Ryan Edward Brown Officer | Jun 25, 2024 | 38,957 | $6.38M | Jun 25, 2024 | Restricted Stock Units |
| Bilal Arif Officer | Jun 24, 2024 | 7,859 | $1.26M | Jun 24, 2024 | Employee Stock Purchase Plan |
| Kathryn Jean Boor Director | Mar 11, 2024 | 761 | $93.55K | Mar 11, 2024 | RESTRICTED STOCK |
| Hans Lennart Rudolf Wigzell Director | Mar 8, 2024 | 15,000 | $1.93M | Mar 8, 2024 | STOCK OPTION EXERCISE |
| Stephen Mayo Director | Mar 5, 2024 | 3,135 | $385.48K | Mar 5, 2024 | RESTRICTED STOCK |
| Ian Michael Estepan Officer | Mar 1, 2024 | 1,565 | $200.02K | Mar 1, 2024 | RESTRICTED STOCK |
| Bilal Arif Officer | Mar 1, 2024 | 2,000 | $257.67K | Mar 1, 2024 | Employee stock unit award(s) |
See a number that looks wrong?